NAD+ Safety Warning and Therapeutic Potential

Human NR data suggest reduced muscle epigenetic aging, while Niagen Bioscience is developing NB4168 for Ataxia Telangiectasia. NAD+-adjacent products continue spreading through beauty, clinics, and longevity stacks, but possible cancer-support effects and a reported death after unlicensed NAD+ IV expose major safety and evidence gaps.